Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608042 | 0.82 | ACHE (0.54) | ALDH1A1ACHE | |
| SCHEMBL18799364 | 0.82 | ACHE (0.54) | ALDH1A1ACHE | |
| SCHEMBL5383680 | 0.75 | ADORA2B (0.38) | ALDH1A1KDM4EHSD17B10KCNA5 | |
| SCHEMBL4243250 | 0.75 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL5384192 | 0.75 | ADORA2B (0.38) | ALDH1A1KDM4EHSD17B10KCNA5 | |
| SCHEMBL5384441 | 0.75 | ADORA2B (0.38) | ALDH1A1KDM4EHSD17B10KCNA5 | |
| SCHEMBL126320 | 0.75 | CASR (0.54) | CASRSMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL4246710 | 0.74 | NPC1 (0.52) | ACHE | |
| SCHEMBL3344245 | 0.74 | ACHE (0.61) | KDM4EACHE | |
| SCHEMBL4244929 | 0.74 | TSHR (0.48) | SMN1; SMN2ALDH1A1KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819710-B1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-09-11 | — | — | US | disclosed |
| US-20080207645-A1 | Pyridothienopyrimidine Derivatives | PAGES SANTACANA LUIS MIGUEL | 2008-08-28 | — | — | US | disclosed |
| EP-1913003-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-04-23 | — | — | EP | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| EP-1819712-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007017078-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006058723-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | PNPO, PDE4A, DPYD | GAA 719/4885CASR 4256/4885SMN1; SMN2 760/4885 |
| US-20080207645-A1 | Pyridothienopyrimidine Derivatives | PDE4A, PDE5A, PDE3B | GAA 908/4885CASR 3630/4885SMN1; SMN2 797/4885 |
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | NR1H2, CBR3, NR4A1 | GAA 4859/4885CASR 1930/4885SMN1; SMN2 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.